Literature DB >> 9429912

Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro.

C Feldman1, R Anderson, A J Theron, G Ramafi, P J Cole, R Wilson.   

Abstract

The effects of the bioactive phospholipids (PL), platelet-activating factor (PAF), lyso-PAF, and lysophosphatidylcholine (LPC) on the beat frequency and structural integrity of human ciliated respiratory epithelium were studied in vitro, in the presence or absence of polymorphonuclear leukocytes (PMNL), the antimicrobial agents, roxithromycin, clarithromycin, and azithromycin and the antioxidative enzymes catalase and superoxide dismutase (SOD). All three PL caused dose-dependent slowing of ciliary beat frequency (CBF) and epithelial damage (ED) at concentrations > or = 1 microgram/ml, which were unaffected by inclusion of the antimicrobial agents and antioxidative enzymes. When epithelial strips were exposed to the combination of PMNL and PL, there was significant potentiation of ciliary dysfunction and ED, which was ameliorated by pretreatment of the PMNL with the antimicrobial agents or by inclusion of catalase, but not SOD. These results demonstrate that LPC, PAF, and lyso-PAF cause epithelial damage by direct mechanisms which are oxidant-independent, as well as by indirect mechanisms involving phagocyte-derived reactive oxidants. Macrolides and azalide antimicrobial agents may have beneficial effects on airway inflammation in asthma and microbial infections by protecting ciliated epithelium against oxidative damage inflicted by PL-sensitized phagocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9429912     DOI: 10.1023/a:1027342424205

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  44 in total

1.  Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils.

Authors:  M T Labro; J el Benna; C Babin-Chevaye
Journal:  J Antimicrob Chemother       Date:  1989-10       Impact factor: 5.790

2.  Persistent neutrophil activation in mild asthma.

Authors:  J Kallenbach; R Baynes; B Fine; D Dajee; W Bezwoda
Journal:  J Allergy Clin Immunol       Date:  1992-08       Impact factor: 10.793

Review 3.  Mucosal inflammation in asthma.

Authors:  R Djukanović; W R Roche; J W Wilson; C R Beasley; O P Twentyman; R H Howarth; S T Holgate
Journal:  Am Rev Respir Dis       Date:  1990-08

4.  Alterations of host response by a long-term treatment of roxithromycin.

Authors:  E Kita; M Sawaki; K Mikasa; K Hamada; S Takeuchi; K Maeda; N Narita
Journal:  J Antimicrob Chemother       Date:  1993-08       Impact factor: 5.790

5.  Platelet-activating factor impairs mucociliary transport and increases plasma leukotriene B4 in man.

Authors:  M M Nieminen; E K Moilanen; M O Koskinen; J I Karvonen; T J Metsä-Ketelä; H Vapaatalo
Journal:  Eur Respir J       Date:  1991-05       Impact factor: 16.671

6.  Effects of dirithromycin and erythromycylamine on human neutrophil degranulation.

Authors:  H Abdelghaffar; E M Mtairag; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

7.  The effect of erythromycin on Pseudomonas aeruginosa and neutrophil mediated epithelial damage.

Authors:  E Tanaka; K Kanthakumar; D R Cundell; K W Tsang; G W Taylor; F Kuze; P J Cole; R Wilson
Journal:  J Antimicrob Chemother       Date:  1994-04       Impact factor: 5.790

8.  Effect of macrolide antibiotics on ciliary motility in rabbit airway epithelium in-vitro.

Authors:  K Takeyama; J Tamaoki; A Chiyotani; E Tagaya; K Konno
Journal:  J Pharm Pharmacol       Date:  1993-08       Impact factor: 3.765

9.  Lysophosphatidylcholine induces mast cell secretion and protein kinase C activation.

Authors:  D L Marquardt; L L Walker
Journal:  J Allergy Clin Immunol       Date:  1991-11       Impact factor: 10.793

10.  Antigen-induced generation of lyso-phospholipids in human airways.

Authors:  F H Chilton; F J Averill; W C Hubbard; A N Fonteh; M Triggiani; M C Liu
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

Review 3.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 4.  Macrolides versus placebo for chronic asthma.

Authors:  Krishna Undela; Lucy Goldsmith; Kayleigh M Kew; Giovanni Ferrara
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

Review 5.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 6.  Anti-inflammatory therapies for cystic fibrosis-related lung disease.

Authors:  David P Nichols; Michael W Konstan; James F Chmiel
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

7.  Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients.

Authors:  Evangelia Fouka; Eleftheria Lamprianidou; Konstantinos Arvanitidis; Eirini Filidou; George Kolios; Paraskevi Miltiades; Emmanouil Paraskakis; Antonios Antoniadis; Ioannis Kotsianidis; Demosthenes Bouros
Journal:  Lung       Date:  2014-07-14       Impact factor: 2.584

Review 8.  Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.

Authors:  Helen C Steel; Annette J Theron; Riana Cockeran; Ronald Anderson; Charles Feldman
Journal:  Mediators Inflamm       Date:  2012-06-21       Impact factor: 4.711

9.  Azithromycin does not improve disease severity in acute experimental pancreatitis.

Authors:  Sebastian Weis; Mario Heindl; Tania Carvalho; Elisa Jentho; Jana Lorenz; Ines Sommerer; Joachim Mössner; Albrecht Hoffmeister
Journal:  PLoS One       Date:  2019-05-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.